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Almost 30 yr ago, proliferating cell nuclear antigen (PCNA) was 
first identified in dividing cells using sera derived from patients 
suffering from systemic lupus erythematosus (Takasaki et al., 
1981). A few years later, the “mother” of all cancer markers had 
been associated with DNA synthesis (Madsen and Celis, 1985), 
but it wasn’t until 1988 that Bauer and Burgers (1988) and Prelich 
and Stillman (1988) discovered that the homotrimeric clamp 
served as a processivity factor for DNA polymerases. In 1992, 
Shivji et al. (1992) showed that PCNA was required for DNA re-
pair, and 10 yr later, it was identified as a target of ubiquitin and 
SUMO (small ubiquitin-like modifier) conjugation after exposure 
to ultraviolet light (Hoege et al., 2002). For a protein that has been 
in the spotlight of modern biochemistry, it is quite remarkable 
that almost nothing is known about its normal cellular turnover.
Insight into this process comes now from the study of an 
unlikely regulator. In this issue, Groehler and Lannigan (2010) 
demonstrate that the relatively poorly characterized ERK8 (extra-
cellular signal-regulated kinase 8) takes center stage in the   
regulation of PCNA stability in primary mammary epithelial cells.   
The ERK family of kinases belongs to the mitogen-activated 
protein kinase superfamily and carries a Thr-Glu-Tyr (T-E-Y) 
activation motif that needs to be phosphorylated to enable ki-
nase activity (Abe et al., 2002). Interestingly, ERK8 also needs 
to bind to chromatin to become active. The authors identified 
a highly conserved PXXXP motif in the C-terminal half of 
ERK8 that appeared to confer autoinhibition, an activity which 
is relieved upon chromatin binding. Relatively close by, in the 
middle of ERK8, resides a PCNA-interacting peptide (PIP) box 
required for the interaction with PCNA (Warbrick, 1998). Curi-
ously, only the chromatin-bound fraction of ERK8 bound to the 
chromatin-bound fraction of PCNA. However, a functional PIP 
box was not required for ERK8 to associate with nuclear DNA in 
the cell. These results argue that ERK8 is not anchored to chro-
matin by PCNA but associates with it independently. Moreover, 
they strongly suggest that ERK8’s PIP box binds to PCNA only 
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when the kinase is associated with chromatin. Importantly, over-
expression of an ERK8 PIP box mutant resulted in destabiliza-
tion of PCNA. The effect on PCNA stability seemed to be highly 
specific, as depletion of ERK8 caused codepletion of PCNA but 
did not lead to a decrease in steady-state levels of a variety of 
other cell cycle regulators.
Why is the interaction with PCNA confined to chromatin? The 
reason is likely due to the fact that ERK8’s PIP box is buried in the 
middle of the protein. Most PCNA-interacting proteins carry their 
PIP box either at the N or C terminus (Vivona and Kelman, 2003). 
One other well-studied example for a protein with an internal PIP 
box is the essential replication factor MCM10 (minichromosome 
maintenance protein 10). MCM10 undergoes cell cycle–regulated 
modification,  which  probably  induces  a  conformational  switch 
that is necessary for the PIP box–mediated interaction with PCNA 
(Das-Bradoo et al., 2006). In the same vein, it is conceivable that 
chromatin association and the accompanying relief of autoinhibi-
tion of ERK8 cause the middle portion of the kinase to change   
its configuration, thereby assuming a functional PIP box domain 
that can be recognized by PCNA. In situations in which the rapid   
unloading of PCNA is required, regulation of ERK8 may be the 
most effective way to dispose of chromatin-bound PCNA, which is 
known to have an exceedingly low exchange rate (Sporbert et al., 
2002). Despite the fact that interaction with ERK8 is necessary 
to stabilize chromatin-bound PCNA, it remains unclear whether 
PCNA is a direct target of ERK8-mediated phosphorylation.
The next goal of Groehler and Lannigan (2010) was to dis-
sect the mechanism underlying the ERK8-regulated degradation 
of PCNA. Based on the consideration that physical contact be-
tween the kinase and PCNA was an integral part of the protection, 
they hypothesized that ERK8 might compete with an E3 ubiquitin 
ligase that may target PCNA via its own PIP box. This turned out 
to be a smart guess because the only candidate to test was the E3 
ligase HDM2, the human homologue of murine double minute 2 
(Momand et al., 1992). In a set of well-controlled experiments, 
the authors not only demonstrate that HDM2 interacts directly 
with and degrades PCNA when ERK8 is absent, but they also ex-
clude indirect effects by p53 and retinoblastoma (Rb) on this pro-
cess. p53 is a direct target of HDM2 and is stabilized when their 
interaction is inhibited (Tao and Levine, 1999). Elevated levels of 
p53 trigger cell cycle arrest concomitant with hypophosphoryla-
tion of Rb, but none of these changes affect the stability of PCNA. 
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It is not hard to imagine that the loss of chromatin-bound PCNA 
has severe consequences for the functionality of DNA replication   
and repair, resulting in chromosome breakage. The authors ar-
gued that a similar level of genome instability should be visible in   
ERK8-depleted cells. This was indeed the case as visualized by   
the accumulation of -H2AX foci and broken DNA (Rogakou   
et al., 1998). Importantly, Groehler and Lannigan (2010) observed 
similar effects in the ERK8 PIP box mutant, further lending cre-
dence to their model. It is worthwhile pointing out that the turn-
over of PCNA expands the spectrum of replication factors whose 
degradation is tightly linked to chromatin. CDT1, a member of 
the prereplication complex (Cook, 2009), is rapidly degraded in 
the face of DNA damage. Its degradation occurs exclusively on 
the chromatin-associated fraction of the protein pool and is de-
pendent on CDT1 binding to PCNA (Arias and Walter, 2005; Hu 
and Xiong, 2006; Senga et al., 2006).
An important question that this study raises is of course to 
what extent, if at all, is PCNA turnover deregulated in cancer 
cells? The commonly high levels of PCNA in transformed cells 
would be most compatible with a deregulation of ERK8 and/or 
HDM2 to provide a significant growth advantage. Indeed, the 
authors show in the last part of their study that in at least two 
transformed cell lines, PCNA is rendered inert to the presence of 
ERK8. They speculate that the underlying reason is a defect in 
HDM2, and although this is the most likely explanation, it still 
needs to be validated. It will be interesting to see how common 
the misregulation of PCNA turnover is in cancer tissues. At this 
point, it is intriguing to envision a dynamic scenario in which   
a two-step mechanism facilitates cell transformation (Fig. 1). 
Initially, deregulation of ERK8 may cause PCNA levels to 
decrease. This would contribute to genome instability and the 
accumulation of new mutations, including those affecting proper 
function of HDM2. In step two, deregulation of HDM2 may 
turn things around and result in an increase of PCNA, support-
ing rapid proliferation.
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Figure 1.  Role of ERK8 in maintaining genome stability. (A) In normal cells, chromatin-bound ERK8 interacts with the chromatin fraction of PCNA, which 
resides at the replication fork (here just shown at the leading strand for simplicity). ERK8 binding inhibits the E3 ubiquitin ligase HDM2 from interacting 
with PCNA. (B) In cancer cells, inactivation of ERK8 enables HDM2 to interact with and ubiquitinate PCNA, targeting it for degradation. A decrease in 
PCNA levels causes an increase in DNA damage, resulting in the accumulation of new mutations. These new mutations may render HDM2 nonfunctional 
(rectangular form), which ultimately results in an increase of PCNA stability and facilitates cell proliferation. The homotrimeric PCNA structure (Protein Data 
Bank ID 2OD8) was generated using the Chimera software program (Pettersen et al., 2004).489 HDM2 ERKs PCNA • Nguyen and Bielinsky
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